Autopsy report · NCT05275439

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

“Development discontinued”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 11 months before it stopped.
• 106 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Shattuck Labs, Inc.

Sponsor type

Industry

Conditions

Acute Myeloid Leukemia; Myelodysplastic Syndromes

Interventions

SL-172154; Azacitidine (AZA); Venetoclax

Participants

106

Sites

23

Countries

Canada, United Kingdom, United States

Trials that died the same way

• A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
  “Program Development discontinued” (84% match in meaning)
• A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
  “Compound development discontinued” (79% match in meaning)
• PRedIcting MEniscal Tears Outcomes After Physical Therapy Treatment
  “Financial support for the project has been discontinued.” (71% match in meaning)
• Safety Study of Nebivolol for COPD Patients
  “Funding was discontinued.” (67% match in meaning)
• Exercise Training Study Before Bariatric Surgery
  “Project during development was discontinued before the enrollment of participants” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.